title: Opposite roles of furin and PC5A in N-cadherin processing.
abstract: We recently demonstrated that lack of Furin-processing of the N-cadherin precursor (proNCAD) in highly invasive melanoma and brain tumor cells results in the cell-surface expression of a nonadhesive protein favoring cell migration and invasion in vitro. Quantitative polymerase chain reaction analysis of malignant human brain tumor cells revealed that of all proprotein convertases (PCs) only the levels of Furin and PC5A are modulated, being inversely (Furin) or directly (PC5A) correlated with brain tumor invasive capacity. Intriguingly, the N-terminal sequence following the Furin-activated NCAD site (RQKR↓DW(161), mouse nomenclature) reveals a second putative PC-processing site (RIRSDR↓DK(189)) located in the first extracellular domain. Cleavage at this site would abolish the adhesive functions of NCAD because of the loss of the critical Trp(161). This was confirmed upon analysis of the fate of the endogenous prosegment of proNCAD in human malignant glioma cells expressing high levels of Furin and low levels of PC5A (U343) or high levels of PC5A and negligible Furin levels (U251). Cellular analyses revealed that Furin is the best activating convertase releasing an ~17-kDa prosegment, whereas PC5A is the major inactivating enzyme resulting in the secretion of an ~20-kDa product. Like expression of proNCAD at the cell surface, cleavage of the NCAD molecule at RIRSDR↓DK(189) renders the U251 cancer cells less adhesive to one another and more migratory. Our work modifies the present view on posttranslational processing and surface expression of classic cadherins and clarifies how NCAD possesses a range of adhesive potentials and plays a critical role in tumor progression.
authors.affiliation: Brain Tumor Research Centre, Montreal Neurological Institute, McGill University, Montréal, Québec, Canada.
authors.forename: Deborah
authors.initials: D
authors.lastname: Maret
authors.forename: Mohamad Seyed
authors.initials: MS
authors.lastname: Sadr
authors.forename: Emad Seyed
authors.initials: ES
authors.lastname: Sadr
authors.forename: David R
authors.initials: DR
authors.lastname: Colman
authors.forename: Rolando F
authors.initials: RF
authors.lastname: Del Maestro
authors.forename: Nabil G
authors.initials: NG
authors.lastname: Seidah
mesh_terms: D015703:Antigens, CD / Q000235:genetics / Q000378:metabolism*; D015153:Blotting, Western; D001932:Brain Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D015820:Cadherins / Q000235:genetics / Q000378:metabolism*; D002465:Cell Movement; D045683:Furin / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D005910:Glioma / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D006367:HeLa Cells; D006801:Humans; D007124:Immunoenzyme Techniques; D045702:Proprotein Convertase 5 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics; D034741:RNA, Small Interfering / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014407:Tumor Cells, Cultured; D014945:Wound Healing
chemical_list: D015703:Antigens, CD; C050361:CDH2 protein, human; D015820:Cadherins; D012333:RNA, Messenger; D034741:RNA, Small Interfering; D045702:Proprotein Convertase 5; C468731:FURIN protein, human; D045683:Furin